Gilead Sciences buying Immunomedics in $21 billion deal

FILE - This April 30, 2020, file photo shows Gilead Sciences headquarters in Foster City, Calif. Shares of Immunomedics more than doubled before the market open on Monday, Sept. 14 after Gilead Sciences said it'll buy the biotechnology company for $21 billion. (AP Photo/Ben Margot, File) Copyright 2020 The Associated Press. All rights re

NEW YORK — Shares of the cancer drug specialist Immunomedics more than doubled before the market opened Monday, a day after its sale to Gilead Sciences for $21 billion was announced.

Gilead said on Sunday that it will pay $88 per share in cash as it seeks to broaden its cancer treatments portfolio. Immunomedics’ drug Trodelvy was granted accelerated approval by the U.S. Food and Drug Administration in April for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. The drug is also being studied for bladder cancer, lung cancer and other solid tumour types.

The deal is expected to close in the fourth quarter.

Advertisement

Shares of Immunomedics, based in New Jersey, jumped to $87.14 in premarket trading, while share of California’s Gilead declined slightly.

The Associated Press

MORE FROM Business

333 Bloor Street East, Toronto, Ontario M4W 1G9 © 2002 - 2024 Rogers Media. All rights reserved.